Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Support holds ⢠Resistance test Support Level: $60.00 Resistance Level: $62.09 BMY has been in a constructive uptrend over the last month, but with shares now testing resistance near $62, the better setup is to wait for a pullback or a confirmed hold above $60 before chasing higher.
Sentiment & News
Key News Insights: ⢠Dividend strength ⢠Portfolio growth ⢠Earnings beat Bristol Myers Squibb is being viewed as a resilient value-and-income stock with strong dividend support, improving portfolio momentum, and near-term upside tied to expected earnings beats despite lingering loss-of-exclusivity risks.
AI Summary
BMY should now be viewed less as a pure patent-cliff decline story and more as a transition case where Eliquis and the growing portfolio are starting to offset legacy erosion, but the investment thesis still hinges on management proving it can convert pipeline and label expansion into durable revenue before margin pressure and future LOE risks overwhelm the base.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.4% |